Nova
Executive Summary
Signs agreement with Grosse Pointe, Michigan-based Mediventures covering the development of approved psychiatric drugs using Mediventures' Quicksolv fast-dissolving drug delivery technology. Nova currently markets a line of psychiatric drugs -- Thorazine, Stelazine, Eskalith and Parnate -- obtained from SmithKline Beecham in a deal completed in July.